MLTX Class Action Reminder – Robbins LLP Reminds MoonLake Immunotherapeutics Stockholders of the Opportunity to Lead the Class Action Lawsuit

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a particular emphasis on dermatology and rheumatology [1]. Class Action Details - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired MoonLake's common stock during this period [1]. Allegations - The complaint outlines several key allegations: - SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F) [3]. - SLK's Nanobody structure does not provide a superior clinical benefit over BIMZELX's monoclonal structure [3]. - The supposed increased tissue penetration of SLK does not translate to clinical efficacy [3]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price dropped significantly [4]. - The stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].